Diabetes and Cancer Treatment Becoming Most Lucrative Path for Biotech Industry
The Bedford Report Provides Equity Research on Dendreon and Biodel
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/04/11 -- In recent years the FDA has been heavily scrutinized for making the approval process more difficult for drug developers. A ground breaking study released this year by the BIO and BioMedTracker finds that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is a mere ten percent. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN) and Biodel, Inc. (NASDAQ: BIOD). Access to the full company reports can be found at:
Previously the rate of approval was one in five to one in six. Oncology drugs faced the toughest road to approval despite the fact that the disease area is the most closely studied in all of drug development.
Janet Woodcock, the head of the FDA's drug division, is quick to dismiss concerns regarding the FDA's approval process. This summer in testimony before the House Energy and Commerce's health subcommittee, Woodcock explained the agency meets more than 90% of deadlines that are part of the drug-review process. She also said so-called first cycle approvals are at a 20-year high with and said more than two-thirds of new drugs being approved within the six-to-10-month time frames given to new drug applications.
The Bedford Report releases investment research on the Apparel Retail Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.
Dendreon's Provenge is a therapy designed to train a patient's immune system to fight prostate cancer. Studies indicate it extended patients' lives by about four months. Recently the FDA approved a third facility where the company will make Provenge.
Biodel Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its proprietary formulation technologies to existing drugs. According to Frost & Sullivan research titled "US Diabetes Drug Delivery -- Patient Perspective," the future of diabetes treatments is in the convenient drug delivery methods. Type-1 diabetic patients are most likely to prefer a twice-a-day oral dosing regimen, while type-2 diabetic patients are also expected to prefer a twice-a-day oral dosing regimen or a twice-a-day patch.
The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at
Contact:
The Bedford Report
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.10.2011 - 12:16 Uhr
Sprache: Deutsch
News-ID 72315
Anzahl Zeichen: 3704
contact information:
Town:
NEW YORK, NY
Kategorie:
Insurance
Diese Pressemitteilung wurde bisher 261 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Diabetes and Cancer Treatment Becoming Most Lucrative Path for Biotech Industry"
steht unter der journalistisch-redaktionellen Verantwortung von
The Bedford Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
